Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents

Table 3

Values of Spearman correlation test and significance level () between clinical and laboratory parameters with age, duration of use, and dose of risperidone in the study sample.

Parameters	ChronologicAge (years)	Bone age (years)	Length of risperidone use (months)	Risperidone dose (mg)	Dose (mg) per kilogram of body weight
BMI	−0.015; (0.872)	0.017; (0.851)	0.026; (0.781)	0.090; (0.327)	−0.217; (0.017)
WC (cm)	0.395; (0.0001)	0.409; (0.0001)	0.030; (0.746)	0.217; (0.017)	−0.151; (0.100)
SBP (mmHg)	0.487; (0.0001)	0.501; (0.0001)	0.202; (0.027)	0.203; (0.027)	−0.080; (0.386)
DBP (mmHg)	0.335; (0.0001)	0.308; (0.001)	0.176; (0.055)	0.126; (0.169)	−0.041; (0.658)
Total cholesterol (mg/dL)	−0.008; (0.928)	−0.051; (0.580)	−0.068; (0.462)	0.119; (0.194)	0.075; (0.415)
LDL cholesterol (mg/dL)	0.057; (0.537)	−0.007; (0.940)	−0.037; (0.687)	0.075; (0.414)	0.008; (0.932)
HDL cholesterol (mg/dL)	−0.171; (0.062)	−0.183; (0.046)	−0.138; (0.133)	0.024; (0.791)	0.120; (0.193)
Triglycerides (mg/dL)	0.126; (0.170)	0.147; (0.108)	−0.023; (0.806)	0.115; (0.213)	−0.25; (0.784)
HOMA-IR index	0.169; (0.065)	0.185; (0.043)	0.021; (0.818)	0.088; (0.340)	−0.092; (0.320)
AST (U/L)	−0.322; (0.0001)	−0.283; (0.002)	0.009; (0.925)	−0.070; (0.450)	0.043; (0.644)
ALT (U/L)	0.019; (0.840)	0.017; (0.858)	−0.023; (0.801)	0.100; (0.277)	−0.013; (0.889)
Leptin (pg/mL)	0.113; (0.217)	0.087; (0.345)	−0.045; (0.624)	−0.012; (0.898)	−0.257; (0.005)

WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure.